Priorix-Tetra™ (GlaxoSmithKline Biologicals) is a combined measles, mumps, rubella and varicella (MMRV) vaccine. Eight studies involving more than 3000 children were reviewed. Compared with co-administration of MMR (Priorix™) and varicella (Varilrix™) vaccines, the MMRV vaccine showed: similar immunogenicity, with immunity shown up to 3 years post-vaccination; a higher rate of fever after the first dose; a slight increase in mild local reactions after the second dose. This MMRV vaccine can be used either as a two-dose vaccine or as a second dose in children primed with separate MMR and/or varicella vaccines, offering a convenient way to introduce varicella vaccination into routine vaccination programmes.
A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra: immunogenicity and safety profile / H., Czajka; V., Schuster; F., Zepp; Esposito, Susanna Maria Roberta; M., Douha; P., Willems. - In: VACCINE. - ISSN 0264-410X. - 27:47(2009), pp. 6504-6511. [10.1016/j.vaccine.2009.07.076]
A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra: immunogenicity and safety profile
Esposito, Susanna Maria Roberta;
2009-01-01
Abstract
Priorix-Tetra™ (GlaxoSmithKline Biologicals) is a combined measles, mumps, rubella and varicella (MMRV) vaccine. Eight studies involving more than 3000 children were reviewed. Compared with co-administration of MMR (Priorix™) and varicella (Varilrix™) vaccines, the MMRV vaccine showed: similar immunogenicity, with immunity shown up to 3 years post-vaccination; a higher rate of fever after the first dose; a slight increase in mild local reactions after the second dose. This MMRV vaccine can be used either as a two-dose vaccine or as a second dose in children primed with separate MMR and/or varicella vaccines, offering a convenient way to introduce varicella vaccination into routine vaccination programmes.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
